CTOs on the Move

Elcelyx Therapeutics

www.elcelyx.com

 
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.elcelyx.com
  • 11995 El Camino Real Suite 305
    San Diego, CA USA 92130-2567
  • Phone: 858.876.1814

Executives

Name Title Contact Details

Funding

Elcelyx Therapeutics raised $40M on 10/01/2015

Similar Companies

PrimeMyBody

PrimeMyBody is a global company that helps people to live wellness and create lifestyle. We formulate life-changing products with quality in mind, and that means using nothing but the best nature has to offer. Being healthy isn`t a fad or a trend... instead, it`s a lifestyle, and our goal is to show the world just that.

WorkCompEDI

WorkCompEDI, Inc. is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harmony Recovery Group

Harmony Recovery Group is a company that owns and operates multiple drug and alcohol rehab facilities across the Eastern and Midwestern United States. Their facilities specialize in providing compassionate and highly individualized, evidence-based subs...

Institut National de Sante Publique du Quebec

Our goal is to advance knowledge and propose crosssectoral strategies and endeavours that will improve the health and well-being of Québecers. The Institut national de santé publique du Québec (INSPQ) was created in 1998 following the adoption of its act of incorporation (RSQ, chapter I-13.1.1). Its experts come from fields as distinct as applied science, health sciences, social sciences, and humanities and work with the health and social services network to develop and pool public health knowledge and skills.

Clinipace

At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.